Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: FOSAMAX

« Back to Dashboard

Summary for Tradename: FOSAMAX

Patents:4
Applicants:2
NDAs:3
Suppliers: see list2

Pharmacology for Tradename: FOSAMAX

Ingredient-typeDiphosphonates
Drug ClassBisphosphonate

Clinical Trials for: FOSAMAX

The Effects of Alendronate After Cure of Primary Hyperparathyroidism
Status: Withdrawn Condition: Hyperparathyroidism

Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury Previously Treated With Teriparatide
Status: Enrolling by invitation Condition: Spinal Cord Injury; Bone Loss; Osteoporosis

Study of Alendronate to Prevent and Treat Osteoporosis in Cystic Fibrosis Patients
Status: Completed Condition: Cystic Fibrosis; Osteoporosis; Bone Diseases, Metabolic

Bioequivalence Study of Alendronate Sodium Tablets 70 mg of Dr. Reddy's Under Fasting Conditions
Status: Completed Condition: Healthy

Pilot Study of Fosamax in Spinal Cord Injury
Status: Terminated Condition: Spinal Cord Injury; Osteoporosis

Alendronate in Juvenile Osteoporosis
Status: Completed Condition: Juvenile Osteoporosis; Low Bone Density; Fractures

Parathyroid Hormone (PTH) With Alendronate for Osteoporosis
Status: Completed Condition: Osteoporosis

A Study of the Bioequivalence of 70-mg Alendronate and 70-mg Alendronate in Combination With 5600 IU Vitamin D (MK0217A-253)(COMPLETED)
Status: Completed Condition: Osteoporosis

Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)
Status: Completed Condition: Osteoporosis Postmenopausal

Safety and Efficacy of Alendronate (Fosamax) in Children With Osteoporosis
Status: Completed Condition: Osteoporosis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck
FOSAMAX PLUS D
alendronate sodium; cholecalciferol
TABLET;ORAL021762Apr 7, 2005RXNo5,994,329*PED<disabled>Y<disabled>
Merck And Co Inc
FOSAMAX
alendronate sodium
TABLET;ORAL020560Oct 20, 2000DISCNNo<disabled><disabled>
Merck
FOSAMAX
alendronate sodium
SOLUTION;ORAL021575Sep 17, 2003RXYes5,462,932*PED<disabled>Y<disabled>
Merck And Co Inc
FOSAMAX
alendronate sodium
TABLET;ORAL020560Oct 20, 2000RXYes<disabled><disabled>
Merck
FOSAMAX PLUS D
alendronate sodium; cholecalciferol
TABLET;ORAL021762Apr 26, 2007RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: FOSAMAX

Drugname Dosage Strength RLD Submissiondate
alendronate sodium and cholecalciferolTablets70 mg/2800 IU and 70 mg/5600 IUFosamax Plus D11/20/2007
alendronate sodiumOral Solution70 mg/75 mLFosamax9/7/2007
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc